The funding was led by Farallon Capital Management. The company reported it plans to bring its first molecular glue program, BTX-1188, into the clinic by the end of 2021, and expand its platform of molecular glues, PROTACs, and monovalent degraders.

In addition, the company plans to advance the clinical development of its lead multikinase inhibitor, BTX-A51, for the treatment of acute myeloid leukemia, myelodysplastic syndromes, and solid tumors.

Cellectis, Sanofi partner on UCART clinical trials
Sanofi has agreed to supply anti-CD52 monoclonal antibody alemtuzumab for use in a lymphodepleting regimen in Cellectis-sponsored universal chimeric antigen...

CytoImmune, City of Hope ink CAR-NK cell therapy agreements
CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through...

Machine-learning system ranks most effective cancer drugs
Scientists successfully trained an ensemble of machine-learning (ML) algorithms to rank clinically relevant cancer drugs based on the drugs' predicted...

Caribou nabs $115M to advance CRISPR-edited cell therapies
Caribou Biosciences has completed $115 million in financing to further develop its next-generation CRISPR technology platform and advance its pipeline...

$105M raised for Senti Bio to develop CAR-NK therapies
Leaps by Bayer, the investment arm of Bayer AG, and Senti Biosciences (Senti Bio) have announced a $105 million series B financing round to develop...